(Bloomberg) -- Illumina Inc.’s blocked $7 billion takeover of cancer-detection provider Grail Inc. should never have been probed by the European Union, according to a top court ruling that ...

Illumina, which founded Grail and spun it off in 2016 only to re-acquire it in 2021 for $7.1 billion, had fought against the European Commission's decision to wield a rarely-used power called ...

Grail, which makes a blood test for cancer, said a vendor’s software issue caused inaccurate letters to be sent to about 400 customers last month. Shareholders are set to vote on Thursday ...

GRAIL said on Tuesday (Aug 13) it has cut about 350 existing jobs as the diagnostics company focuses on the development of its flagship cancer-detection test Galleri, sending its shares up more than ...

Grail said in a Tuesday press release that it’d sold more than 215,000 tests as of the end of June — it offers the test on a Galleri website, through a telemedicine provider, for $949.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it ...

Antitrust regulators in Brussels had probed the acquisition despite Grail having no revenues or presence in the EU, usually a requirement for transactions to be investigated, and ultimately forced ...

Despite the planet’s growing plastic pollution crisis, petroleum-based polymers have become an integral part of modern life. They make cars and airplanes lighter and more energy efficient. They ...

Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the ...